FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in TreatmentPublished: February 20, 2025On January 27,…
